Pressmeddelanden från Pila Pharma

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

PILA PHARMA CLARIFIES: DECISION TO POSTPONE THE ANNUAL REPORT TO AWAIT CONCLUSION ON PRECLINICAL OBESITY STUDIES I förrgår 18:15

PILA PHARMA POSTPONES THE PUBLICATION OF THE ANNUAL REPORT AND THE ANNUAL GENERAL MEETING 05 mar 16:15

PILA PHARMA: TO PARTICIPATE IN PHARMA PARTNERSHIP CONFERENCE BIO EUROPE SPRING IN LISBON, MARCH 23-25 05 mar 15:30

PILA PHARMA: TO2 WARRANTS CONVERTED, SHARES ARE NOW TRADABLE - CEO & FOUNDER'S PARTICIPATION DISCLOSED 17 feb 16:00

PILA PHARMA: MANAGEMENT TEAM COMMENTS ON OUTCOME OF TO2 WARRANTS 17 feb 12:00

PILA PHARMA ANNOUNCES THE OUTCOME IN THE EXERCISE OF WARRANTS OF SERIES TO2 12 feb 12:00

PILA PHARMA: Upcoming last days for exercise with the warrants of series TO2 11 feb 16:30

PILA PHARMA: CEO REPORT INTERVIEW AND Q&A ON CLINICAL PLANS, TO2 WARRANTS AND MORE, AVAILABLE FOR REPLAY NOW 10 feb 11:00

PILA PHARMA: INVITATION TO LIVE H2 / YEAR-END REPORT INTERVIEW AND Q&A TODAY AT 14:00 CET 10 feb 08:30

PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s year-end report for the period January - December 2025.09 feb 15:00

PILA PHARMA PREPARES CLINICAL TRIAL APPLICATION IN RARE DISEASE ERYTHROMELALGIA 05 feb 08:45

THE EXERCISE PRICE FOR THE WARRANTS OF SERIES TO2 IN PILA PHARMA HAS BEEN DETERMINED TO SEK 1.50 AND THE EXERCISE PERIOD COMMENCES TODAY 05 feb 08:40

PILA PHARMA ACCELERATES THE PUBLICATION OF THE INTERIM REPORT OF THE SECOND HALF OF 2025 27 jan 08:55

PILA PHARMA: INVITATION TO LIVE Q&A TODAY, JANUARY 27, REGARDING PRECLINICAL STUDIES AND UPCOMING CLINICAL STUDIES 26 jan 11:00

PILA PHARMA SIGNS WITH NEW CLINICAL CRO TO PREPARE FOR CLINICAL PHASE IN OBESITY AFTER PRECLINICAL OBESITY STUDIES 16 jan 09:30

PILA PHARMA: CEO PARTICIPATED IN SWEDISH INVESTMENT PODCAST MARKET MAKERS 16 jan 08:30

PILA PHARMA: ANALYST GROUP INITIATES NEW EQUITY RESEARCH COVERAGE - BASE CASE TARGET OF SEK 6.30 05 jan 09:05

PILA PHARMA: INVITED TO PRESENT AT BIOTECH SHOWCASE / J.P MORGAN HEALTHCARE WEEK IN SAN FRANCISCO, JANUARY 13, 2026 02 jan 11:09

PILA PHARMA: CEO GUSTAV H. GRAM ACQUIRES ADDITIONAL SHARES 19 dec 2025 08:45

PILA PHARMA: PRECLINICAL STUDIES OF XEN-D0501 IN OBESITY INITIATED 04 dec 2025 16:00

PILA PHARMA ANNOUNCES PRE-CLINICAL OBESITY AND AMYLIN SPECIALIST PROFESSOR THOMAS LUTZ TO JOIN AS SCIENTIFIC ADVISER 27 okt 2025 16:00

PILA PHARMA: UPCOMING PARTICIPATION IN OBESITYWEEK AND AMERICAN HEART ASSOCIATION CONVENTION 07 okt 2025 11:45

PILA PHARMA: CEO GUSTAV H. GRAM ACQUIRES ADDITIONAL SHARES 30 sep 2025 17:15

PILA PHARMA ENTERS INTO AGREEMENT WITH THE CRO GUBRA ON PRECLINICAL TRIALS OF XEN-D0501 IN OBESITY 08 sep 2025 11:55

PILA PHARMA TO PARTICIPATE AT THE 61ST EASD DIABETES & OBESITY SCIENTIFIC MEETING, NEXT WEEK 16-19 SEPTEMBER IN VIENNA 08 sep 2025 11:25

PILA PHARMA: ALL H1 REPORT & INVESTOR INTERVIEWS NOW ONLINE 29 aug 2025 14:00

PILA PHARMA: H1 REPORT INTERVIEW RECORDING WITH DIREKT STUDIOS - CEO COMMENTS ON HEAVILY OVERSUBSCRIBED RIGHTS ISSUE AND PLANS 29 aug 2025 13:30

PILA PHARMA: CEO VISITS INVESTMENT PODCAST 10X TO COMMENT ON HEAVILY OVERSUBSCRIBED ISSUE (293,5%) AND OBESITY PLANS 27 aug 2025 08:00

PILA PHARMA PUBLISHES INTERIM REPORT (1 JANUARY - 30 JUNE 2025)21 aug 2025 15:55

PILA PHARMA: INVITATION TO LIVE H1 REPORT INTERVIEW AND Q&A 21 aug 2025 15:30

PILA PHARMA ANNOUNCES THE COMPLETION OF REGISTRATION OF SHARES IN THE RIGHTS ISSUE AND ITS ASSOCIATED DIRECTED ISSUES, MARKING THE END OF THE RIGHTS ISSUE PROCESS 31 jul 2025 15:30

PILA PHARMA announces updated dates for last day of trading with paid subscribed units and first day of trading in new shares 23 jul 2025 08:55

The board of directors of PILA PHARMA has resolved to carry out a directed issue of units to underwriters in the previously ended rights issue 21 jul 2025 13:45

PILA PHARMA announces the outcome of its oversubscribed rights issue and resolves on a directed issue for over-allotment 14 jul 2025 13:20

THE LAST DAY OF SUBSCRIPTION OF UNITS IN PILA PHARMA'S RIGHTS ISSUE OF UNITS 10 jul 2025 10:20

THE LAST DAY OF TRADING IN UNIT RIGHTS IN PILA PHARMA'S RIGHTS ISSUE OF UNITS 09 jul 2025 09:25

PILA PHARMA: INVESTMENT PODCAST GÖTT TJÖT OM AKTIER INTERVIEWS CEO ABOUT RIGHTS ISSUE AND OBESITY ASPIRATIONS 08 jul 2025 09:16

PILA PHARMA: FINWIRE SIT-DOWN INTERVIEW TALKING FUNDRAISING AND BET ON OBESITY 07 jul 2025 11:30

PILA PHARMA: NEW INTERVIEW ON RIGHTS ISSUE AND BET ON OBESITY WITH DIREKT STUDIOS 04 jul 2025 14:00

CEO DISCUSSES ONGOING RIGHTS ISSUE AND BET ON OBESITY WITH INVESTMENT PODCAST 10X 01 jul 2025 10:41

The subscription period in PILA PHARMA's rights issue of units begins today 01 jul 2025 09:05

PILA PHARMA DISCUSSES ITS FINANCING ROUND WITH HELGE LARSEN & PROINVESTOR 25 jun 2025 13:30

THE LAST DAY OF TRADING IN PILA PHARMA'S SHARES INCLUDING THE RIGHT TO RECEIVE UNIT RIGHTS 25 jun 2025 13:00

PILA PHARMA PUBLISHES PROSPECTUS IN CONNECTION WITH THE ANNOUNCED RIGHTS ISSUE OF UNITS 19 jun 2025 15:20

THE BOARD OF DIRECTORS OF PILA PHARMA HAS RESOLVED TO CARRY OUT A RIGHTS ISSUE OF UNITS OF APPROXIMATELY SEK 20 MILLION 18 jun 2025 13:48

PILA PHARMA: ALL INVESTOR PRESENTATION RECORDINGS NOW ONLINE 17 jun 2025 14:48

PILA PHARMA VISITED DIREKT STUDIOS' INVESTMENT CHANNEL 16 jun 2025 15:53

PILA PHARMA PARTICIPATED IN INVESTMENT PODCAST 10X 10 jun 2025 17:00

PILA PHARMA INVITES TO AFTER-WORK MINGLE IN STOCKHOLM 10 jun 2025 16:30

PILA PHARMA UPCOMING INVESTOR PRESENTATIONS IN STOCKHOLM 10 jun 2025 11:01

PILA PHARMA DISCUSSED ITS POTENTIAL ROLE IN OBESITY & DIABETES WITH HELGE LARSEN & PROINVESTOR 04 jun 2025 16:15

PILA PHARMA TO RE-VISIT PROINVESTOR WITH HELGE LARSEN TO DISCUSS THE COMPANY'S AMBITIONS IN OBESITY & DIABETES 30 apr 2025 08:30

PILA PHARMA PROACTIVELY MOVES FORWARD WITH PP-CT03 CLINICAL TRIAL APPLICATION FOR STUDY IN PEOPLE LIVING WITH OBESITY AND DIABETES 29 apr 2025 16:15

KOMMUNIKÉ FRÅN ÅRSSTÄMMA I PILA PHARMA AB 2025 25 apr 2025 17:00

PILA PHARMA UPCOMING INVESTOR MEETINGS 23 apr 2025 15:28

PILA PHARMA: REMINDER - LAST DAY FOR SHAREHOLDER REGISTRATION FOR ANNUAL GENERAL MEETING 27 mar 2025 10:00

KALLELSE TILL ÅRSSTÄMMA I PILA PHARMA AB 27 mar 2025 08:30

PILA PHARMA PUBLISHES THE ANNUAL REPORT 2024 27 feb 2025 08:00

PILA PHARMA PUBLISHES YEAR-END REPORT (1 JANUARY - 31 DECEMBER 2024)24 feb 2025 16:45

PILA PHARMA INVITES TO H2 REPORT WEBINAR & INVESTOR Q&A 18 dec 2024 15:00

PILA PHARMA ANNOUNCES PRECLINICAL PROOF-OF-CONCEPT ACHIEVED IN CARDIOVASCULAR DISEASE STUDY 13 dec 2024 11:36

PILA PHARMA ANNOUNCES NEW CHIEF FINANCIAL OFFICER (CFO)21 nov 2024 10:00

PILA PHARMA ANNOUNCES INITIATION OF STUDY IN PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE 20 nov 2024 17:00

PILA PHARMA INVITES TO NORDIC INVESTOR MEETINGS 19 nov 2024 12:03

PILA PHARMA AB Chairman & CEO increase their holdings 14 nov 2024 08:50

PILA PHARMA TO PARTICIPATE IN DANISH INVESTMENT PODCAST "MILLIONÆRKLUBBEN"14 nov 2024 08:00

PILA PHARMA ANNOUNCES SELECTION OF CLINICAL TRIAL SITE AND DECISION TO SEEK SCIENTIFIC ADVICE FOR OPTIMIZED PP-CT03 STUDY DESIGN 13 nov 2024 08:00

PILA PHARMA ANNOUNCES PROGRESSION AND CO-SPONSORSHIP OF PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE 17 okt 2024 08:00

PILA PHARMA INFORMS OF OPTIMIZATION CHANGES TO TRIAL PLAN 02 sep 2024 12:04

CEO Gustav H. Gram increases holding in PILA PHARMA AB 27 aug 2024 08:00

PILA PHARMA publishes interim report (1 January - 30 June 2024)26 aug 2024 15:07

PILA PHARMA INVITES TO INVESTOR Q&A & PRESENTATIONS 25 jul 2024 20:00

PILA PHARMA'S BOARD OF DIRECTORS ANNOUNCES COMPLETION OF A FULLY SUBSCRIBED DIRECTED ISSUE OF APPROXIMATELY SEK 10 MILLION 24 jul 2024 18:00

PILA PHARMA INKS AGREEMENT WITH LINDUS HEALTH ABOUT NEXT CLINICAL TRIAL WITH SAFETY AND OBESITY READOUTS 16 jul 2024 17:00

PILA PHARMA'S BOARD OF DIRECTORS HAS RESOLVED TO CARRY OUT A DIRECTED ISSUE OF SHARES OF APPROXIMATELY SEK 10.0 MILLION 26 jun 2024 11:19

Clarification: PILA PHARMA SPONSORS INTERNATIONAL DIABETES & NUTRITION CONFERENCE 26 jun 2024 08:00

PILA PHARMA SPONSORS INTERNATIONAL DIABETES & NUTRITION CONFERENCE 11 jun 2024 17:18

PILA PHARMA PRESENTS TOMORROW AT "AKTIESPARARNA"23 maj 2024 08:40

PILA PHARMA PRESENTS TODAY AT REDEYE THEME: DIABETES 15 maj 2024 13:26

CEO Gustav H. Gram increases holding in Pila Pharma AB 07 maj 2024 15:28

PILA PHARMA RECEIVES AWARD OF INNOVATION GRANT 22 apr 2024 15:25

REMINDER: PILA PHARMA ABs NEXT FINANCIAL REPORT IS DUE IN AUGUST 19 apr 2024 09:45

PILA PHARMA AB APPOINTS NEW CHAIRMAN OF THE BOARD AND CEO 18 apr 2024 17:40

KOMMUNIKE FRÅN ÅRSSTÄMMA I PILA PHARMA AB 2024 11 apr 2024 13:30

PILA PHARMA TO PRESENT IN ODENSE, DENMARK & ONLINE 21 mar 2024 10:05

CEO COMMENT ON NOMINATION TO BECOME NEXT CHAIRMAN 21 mar 2024 09:59

KALLELSE TILL ÅRSSTÄMMA I PILA PHARMA AB 20 mar 2024 19:23

PILA PHARMA PUBLISHES THE ANNUAL REPORT 2023 20 mar 2024 17:34

PILA PHARMA ADVANCES THE PUBLICATION OF THE ANNUAL REPORT 2023 19 mar 2024 08:00

PILA PHARMA INVITES YOU TO INVESTOR MEETINGS 01 mar 2024 16:00

PILA PHARMA INVITES TO INVESTOR MEETING IN KOLDING, DENMARK 28 feb 2024 13:13

PILA PHARMA INVITES TO ONLINE INVESTOR MEETING & EARNINGS CALL 28 feb 2024 08:00

PILA PHARMA publishes year-end report (1 January - 31 December 2023)16 jan 2024 09:19

PILA PHARMA HAS BEEN SELECTED TO PARTICIPATE IN THE REGIONAL SCALE-UP PROGRAM "10 X HEALTH"05 dec 2023 19:30

Pila Pharma AB announces outcome in the rights issue 29 nov 2023 11:30

THE ONGOING RIGHTS ISSUE IN PILA PHARMA HAS ENTERED ITS LAST SUBSCRIPTION WEEK AND WILL END MONDAY 4 DECEMBER. THE LAST DAY OF TRADING SUBSCRIPTION RIGHTS IS WEDNESDAY 29 NOVEMBER 26 nov 2023 22:06

PILA PHARMA WILL PRESENT AT "STORA AKTIEDAGARNA" IN STOCKHOLM TOMORROW, 27 NOVEMBER 2023 AT 8:00 CET 26 nov 2023 21:45

PILA PHARMA ANNOUNCES PRECLINICAL RESEARCH COLLABORATION 17 nov 2023 09:59

PILA PHARMA PUBLISHES INFORMATION MEMORANDUM 25 okt 2023 08:15

PILA PHARMA PUBLISHES INTERIM REPORT (1 July - 30 September 2023)